Exploring Melezitose as a Potential Therapeutic Agent in Lung Cancer: Inhibitory Effects on Cell Proliferation and EMT-Mediated Signaling in A549 Cells

ABSTRACT

Background: Lung cancer is one of the most common cancers worldwide and a leading cause of cancer-related deaths. The study delves into melezitose, a naturally occurring compound known for its biocompatibility. Purpose: This study aims to uncover its therapeutic potential and molecular mechanisms within lung cancer, particularly in A549 cells. Melezitose’s impact on inhibiting cell proliferation and influencing epithelial-mesenchymal transitions (EMT) was the primary focus. Materials and Methods: In a time-dependent manner, A549 cells, representative of lung adenocarcinoma (LUAD), underwent melezitose treatment. Analysis of cytotoxicity by MTT assay, cell migration assay, and its responsible genes were analyzed by reverse transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) kit method. Results: The MTT assay indicated a significant reduction in A549 cell growth after 48 hours of melezitose treatment. Additionally, melezitose induced G1 phase cell arrest and stimulated apoptosis in A549 cells. Subsequent determination of IC50 values represents the concentration at which melezitose inhibits 50% of cell growth. The study also investigated EMT-related gene expression like claudin 1 (CLD1), E-cadherin (ECADH), SNAIL1, SLUG, and vimentin (VIM) through RT-PCR. The findings revealed strong binding associations between melezitose and these EMT targets, suggesting a potential regulatory role of melezitose in impeding EMT processes. Conclusion: Overall, this study illuminates the significant role of melezitose in lung cancer. Its observed inhibition of lung cancer cell proliferation and its influential impact on EMT-related gene expression highlights. Melezitose has potential as a therapeutic agent, particularly in the context of NSCC. The multifaceted effects of melezitose on A549 cells open promising avenues for advancing our understanding of this disease and developing innovative therapeutic strategies.

KEYWORDS

• Melezitose
• lung cancer
• A549 cells
• epithelial-mesenchymal transitions
• therapeutic potential

Showing references and in-text citations exactly as published.

• DOI10.1177/09731296241251545Copy

RELATED ARTICLES

Matched on section and article type within this issue of Pharmacogn. Mag..

• Article · VOLUME 20, ISSUE 4Fraxinus excelsior L. for Prevention of Capecitabine-induced Enterocolitis in Rat: An Integrated Biochemical, Molecular, and Histopathological StudyLi Li, HaiYan Tan, TianLu Su · pp. 1086–1099Original Research ArticleSame type: Article
• Article · VOLUME 20, ISSUE 4Lijing-Anfei Decoction Attenuates COPD in a Mouse Model: Network Pharmacology Analysis, Molecular Docking, and Experimental ValidationJiajia Zhu, Jie Liu, Wei Jia, Guoqiang Shao, Haizhu Xu · pp. 1100–1113Original Research ArticleSame type: Article
• Article · VOLUME 20, ISSUE 4Anticancer Effects of Vaccinium arctostaphylos L. through HOTAIR/miR-124/Notch1 Axis of Hepatocellular Carcinoma in Rat: A Biochemical, Molecular, Immunohistochemical, and Histopathological ApproachesChengchen Zhou, Xiaoling Qin, Jingyi Wang, Yongchang Liu · pp. 1114–1127Original Research ArticleSame type: Article
• Article · VOLUME 20, ISSUE 4Eriocitrin in the Treatment of Diabetic Nephropathy: Amelioration Against Oxidative Burst and Inflammation ApproachHui Deng, Yarong Li, Shulan Han, Min Lan, Liqin Cui, Tahani Awad Alahmadi, Sulaiman Ali Alharbi, Zhong Li · pp. 1128–1140Original Research ArticleSame type: Article